JP2005534620A5 - - Google Patents

Download PDF

Info

Publication number
JP2005534620A5
JP2005534620A5 JP2003582140A JP2003582140A JP2005534620A5 JP 2005534620 A5 JP2005534620 A5 JP 2005534620A5 JP 2003582140 A JP2003582140 A JP 2003582140A JP 2003582140 A JP2003582140 A JP 2003582140A JP 2005534620 A5 JP2005534620 A5 JP 2005534620A5
Authority
JP
Japan
Prior art keywords
group
formula
alkyl
hydrogen
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003582140A
Other languages
English (en)
Japanese (ja)
Other versions
JP4634717B2 (ja
JP2005534620A (ja
Filing date
Publication date
Priority claimed from FR0204567A external-priority patent/FR2838439B1/fr
Application filed filed Critical
Publication of JP2005534620A publication Critical patent/JP2005534620A/ja
Publication of JP2005534620A5 publication Critical patent/JP2005534620A5/ja
Application granted granted Critical
Publication of JP4634717B2 publication Critical patent/JP4634717B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003582140A 2002-04-11 2003-04-10 テルフェニル誘導体、それらの製造およびそれらを含む組成物 Expired - Fee Related JP4634717B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0204567A FR2838439B1 (fr) 2002-04-11 2002-04-11 Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
PCT/FR2003/001134 WO2003084943A2 (fr) 2002-04-11 2003-04-10 Derives de terphenyle, leur preparation, les compositions pharmaceutiques en contenant

Publications (3)

Publication Number Publication Date
JP2005534620A JP2005534620A (ja) 2005-11-17
JP2005534620A5 true JP2005534620A5 (https=) 2006-06-01
JP4634717B2 JP4634717B2 (ja) 2011-02-16

Family

ID=28459770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003582140A Expired - Fee Related JP4634717B2 (ja) 2002-04-11 2003-04-10 テルフェニル誘導体、それらの製造およびそれらを含む組成物

Country Status (13)

Country Link
US (1) US7390924B2 (https=)
EP (1) EP1497274B1 (https=)
JP (1) JP4634717B2 (https=)
CN (1) CN100432062C (https=)
AT (1) ATE339408T1 (https=)
AU (1) AU2003246811A1 (https=)
BR (1) BR0309106A (https=)
CA (1) CA2481392A1 (https=)
DE (1) DE60308349T2 (https=)
FR (1) FR2838439B1 (https=)
MX (1) MXPA04009981A (https=)
PL (1) PL374024A1 (https=)
WO (1) WO2003084943A2 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082191A2 (en) 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
JP2006510597A (ja) 2002-09-27 2006-03-30 メルク エンド カムパニー インコーポレーテッド 置換ピリミジン類
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
FR2856684B1 (fr) 2003-06-26 2008-04-11 Sanofi Synthelabo Derives de diphenylpyridine, leur preparation et leur application en therapeutique
RU2360909C2 (ru) 2004-01-28 2009-07-10 Ф.Хоффманн-Ля Рош Аг Новые спиропентациклические соединения
EP1574211A1 (en) * 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
JP4760139B2 (ja) * 2004-05-28 2011-08-31 田辺三菱製薬株式会社 ピロリジン誘導体およびその製法
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
GB0416508D0 (en) * 2004-07-23 2004-08-25 Merck Sharp & Dohme Therapeutic agents
FR2876691B1 (fr) * 2004-10-18 2006-12-29 Sanofi Aventis Sa Derives de pyridine, leur preparation, leur application en therapeutique
RU2391337C2 (ru) 2004-11-09 2010-06-10 Ф.Хоффманн-Ля Рош Аг Производные дибензосуберона
WO2006079406A1 (en) * 2005-01-25 2006-08-03 Merck Patent Gmbh Mesogenic compounds, liquid crystal medium and liquid crystal display
EP1910290A2 (en) 2005-06-30 2008-04-16 Prosidion Limited Gpcr agonists
FR2899899A1 (fr) * 2006-04-14 2007-10-19 Sanofi Aventis Sa Derives d'aminomethyl pyridine, leur preparation et leur application en therapeutique
ES2333539T3 (es) * 2006-04-21 2010-02-23 Cellzome Limited Derivados de terfenilo para el tratamiento de la enfermedad de alzheimer.
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EA016507B1 (ru) 2007-01-04 2012-05-30 Прозидион Лимитед Пиперидиновые агонисты gpcr
PE20081849A1 (es) 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
US20100048632A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine GPCR Agonists
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
CL2008000018A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
GB2486631A (en) * 2010-12-01 2012-06-27 Univ Sheffield Phenol/quinone boronic acids/esters and method of preparation thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
CN105175241B (zh) * 2015-08-28 2017-09-29 浙江工业大学 三联苯类化合物及其制备方法和应用
WO2018159650A1 (ja) * 2017-02-28 2018-09-07 東レ株式会社 グアニジン誘導体及びその医薬用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916145A (en) * 1987-07-10 1990-04-10 Hoffmann-La Roche Inc. Substituted n-[(pyridyl)alkyl]aryl-carboxamide
FR2800375B1 (fr) * 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant

Similar Documents

Publication Publication Date Title
JP2005534620A5 (https=)
CN113717156B (zh) Egfr抑制剂、其制备方法及用途
JP6866967B2 (ja) サイクリン依存性キナーゼcdk9の新規阻害剤
US20040082661A1 (en) Urea derivatives having vanilloid receptor (vr1) antagonist activity
RU2315043C2 (ru) Амидное производное, фармацевтическая композиция и терапевтические средства на его основе
RU2008116313A (ru) Диарилминсодержащие соединения, композиции и их примеение в качестве модуляторов рецепторов с-кit
JP2006524222A5 (https=)
KR100674813B1 (ko) N-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
Patel et al. Synthesis, biological evaluation and 3D QSAR study of 2, 4-disubstituted quinolines as anti-tuberculosis agents
JP2019536766A (ja) 2−置換芳香族環−ピリミジン系誘導体及びその調製と医学的用途
CN102250065A (zh) 取代的三嗪苯脲衍生物及其用途
RU2005113153A (ru) Новые пиримидинамидные производные и их применение
IE50186B1 (en) 3-aminopropoxy derivatives,their preparation and pharmaceutical compositions containing them
RU2008144952A (ru) Производные аминометилпиридина, их получение и их применение в терапии
DE69207301T2 (de) Substituierte 3-Piperazinylalkyl 2,3-Dihydro-4H-1,3-Benzoxazin-4-One, deren Herstellung und Verwendung in Heilkunde
JPWO2009041559A1 (ja) インダゾールアクリル酸アミド化合物
BR0205683A (pt) Processo para a preparação de derivados de piperazina, e, mesilato de um composto
Li et al. Ni/NHC-catalyzed cross-coupling of methyl sulfinates and amines for direct access to sulfinamides
TW381023B (en) Use of 5-acyl-1,4-dihydropyridines for the treatment of disorders of the central nervous system
EA027882B1 (ru) Этинильные производные в качестве антагонистов метаботропного глутаматного рецептора
HRP20120833T1 (hr) Derivati benzilpiperazina, korisni u lijeäśenju gastrointestinalnih poremeä†aja
JP2006522034A5 (https=)
AR045548A1 (es) Derivados de imidazol
RU2009147291A (ru) Применение ингибиторов raf для лечения рака щитовидной железы
Matasi et al. 2-(2-Furanyl)-7-phenyl [1, 2, 4] triazolo [1, 5-c] pyrimidin-5-amine analogs: highly potent, orally active, adenosine A2A antagonists. Part 1